On October 15, Pfizer Pharmaceuticals announced that HYMPAVZI has recently been approved by the US Food and Drug Administration to regularly treat patients with hemophilia A or hemophilia B without coagulation factor inhibitors to reduce the incidence of bleeding. HYMPAVZI is Pfizer's second hemophilia treatment approved by the FDA this year.

On October 15, Pfizer Pharmaceuticals announced that HYMPAVZI has recently been approved by the US Food and Drug Administration to regularly treat patients with hemophilia A or hemophilia B without coagulation factor inhibitors to reduce the incidence of bleeding. HYMPAVZI is Pfizer's second hemophilia treatment approved by the FDA this year.